Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2509181 | 1.00 | THRB (0.44) | THRBALDH1A1TSHRHTTSMN1; SMN2 | |
| SCHEMBL2509180 | 1.00 | THRB (0.44) | THRBALDH1A1TSHRHTTSMN1; SMN2 | |
| SCHEMBL16522193 | 0.87 | CHRM2 (0.39) | THRBALDH1A1TSHRHTTSMN1; SMN2 | |
| SCHEMBL21294835 | 0.85 | THRB (0.42) | THRBALDH1A1TSHRHTTSMN1; SMN2 | |
| SCHEMBL16617840 | 0.85 | THRB (0.42) | THRBALDH1A1TSHRHTTSMN1; SMN2 | |
| SCHEMBL21312252 | 0.85 | THRB (0.42) | THRBALDH1A1TSHRHTTSMN1; SMN2 | |
| SCHEMBL16617853 | 0.85 | THRB (0.42) | THRBALDH1A1TSHRHTTSMN1; SMN2 | |
| SCHEMBL20153574 | 0.84 | MAPK1 (0.41) | THRBALDH1A1CHRM2CHRM3 | |
| SCHEMBL18926524 | 0.84 | MAPK1 (0.41) | THRBALDH1A1CHRM2CHRM3 | |
| SCHEMBL18213529 | 0.84 | MAPK1 (0.41) | THRBALDH1A1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-0238305-B1 | 4,4-BIS(4-HYDROXYPHENYL)CYCLOHEXANECARBOXYLIC ACID DERIVATIVES AND PROCESS FOR PREPARING SAME | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-05-23 | — | — | EP | disclosed |
| US-4814488-A | STARTING MATERIALS FOR POLYMERS | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1989-03-21 | — | — | US | disclosed |
| US-4755616-A | 4,4-bis(4-hydroxyphenyl)cyclohexanecarboxylic acid derivatives and process for preparing same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1988-07-05 | — | — | US | disclosed |
| EP-0238305-A1 | 4,4-Bis(4-hydroxyphenyl)cyclohexanecarboxylic acid derivatives and process for preparing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | THRB 2139/4885ALDH1A1 1614/4885TSHR 2833/4885 |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | SYK, BTK, LCK | THRB 2139/4885ALDH1A1 1614/4885TSHR 2833/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | THRB 2139/4885ALDH1A1 1614/4885TSHR 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.